Novo Nordisk A/S

Equities

NOVO B

DK0062498333

Pharmaceuticals

Market Closed - Nasdaq Copenhagen 10:59:34 2024-04-24 am EDT 5-day change 1st Jan Change
878.7 DKK -1.41% Intraday chart for Novo Nordisk A/S +1.29% +25.87%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Sector Update: Health Care Stocks Slipping Late Afternoon MT
Sector Update: Health Care MT
Novo Nordisk's Wegovy FDA Approval for Heart Health Opens Door to Medicare Access, KKF Says MT
US Senate committee investigates pricing of Novo's Ozempic and Wegovy RE
Novo Nordisk Probed by Senate Committee on Weight-Loss Drug Prices DJ
NOVO NORDISK : Bernstein maintains a Buy rating ZD
Germany's Evotec appoints Christian Wojczewski as CEO RE
UK stocks may finally be back in fashion RE
Health Care Climbs on Earnings Hopes -- Health Care Roundup DJ
Eli Lilly to acquire manufacturing facility from Nexus Pharma RE
India's Biocon developing its own version of Wegovy, clinical trial likely next year RE
More than 250 websites selling fake weight-loss drugs reported by anti-counterfeit firm RE
Biophytis: patent application filed in the field of obesity CF
Health Care Falls as Risk Aversion Weighs on Obesity Drug Makers -- Health Care Roundup DJ
European Equities Close Mixed in Friday Trading; German Inflation Slows, UK GDP Rises MT
Weight-Loss Drugs Like Wegovy Don't Cause Suicidal Thoughts, EU Says DJ
Sector Update: Health Care Stocks Steady Pre-Bell Friday MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says MT
European Medicines Agency Finds No Increased Suicide Risk Linked to Weight-loss Drugs MT
Novo Nordisk's Wegovy, Ozempic Have No Added Suicide Risk, EU Says MT
European Medicines Agency Finds No Increased Suicide Risk Link to Novo Nordisk's Wegovy, Ozempic MT
BMO Capital Starts Novo Nordisk With Outperform Rating, $163 Price Target MT
EU regulator finds no link between weight-loss drugs and suicidal thoughts RE
Gerresheimer shares down on outlook, but key contracts confirmed RE
Gerresheimer supplies 'key players' in GLP-1 drugs market, CEO says RE
Chart Novo Nordisk A/S
More charts
Novo Nordisk A/S specializes in the design, manufacture and marketing of pharmaceutical products. Net sales break down by family of products as follows: - diabetes and obesity treatment products (92.6%); - rare disease treatment products (7.4%): intended for the treatment of haemophilia, blood disorders, hormonal disorders, etc. Net sales are distributed geographically as follows: Europe/Middle East/Africa (21.9%), the United States (54.9%), North America (3.9%), China (7.2%) and other (12.1%).
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
878.7 DKK
Average target price
904.2 DKK
Spread / Average Target
+2.90%
Consensus
  1. Stock Market
  2. Equities
  3. NOVO B Stock
  4. News Novo Nordisk A/S
  5. JPMorgan Upgrades Novo Nordisk to Overweight From Neutral